mirror of
https://github.com/msberends/AMR.git
synced 2025-07-17 15:13:15 +02:00
prerelease 1.8.1
This commit is contained in:
@ -44,11 +44,7 @@
|
||||
</button>
|
||||
<span class="navbar-brand">
|
||||
<a class="navbar-link" href="../index.html">AMR (for R)</a>
|
||||
<<<<<<< HEAD
|
||||
<span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="Released version">1.8.1</span>
|
||||
=======
|
||||
<span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="Released version">1.8.0.9005</span>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
</span>
|
||||
</div>
|
||||
|
||||
@ -189,7 +185,7 @@
|
||||
|
||||
|
||||
|
||||
</header><script src="MDR_files/accessible-code-block-0.0.1/empty-anchor.js"></script><div class="row">
|
||||
</header><div class="row">
|
||||
<div class="col-md-9 contents">
|
||||
<div class="page-header toc-ignore">
|
||||
<h1 data-toc-skip>How to determine multi-drug resistance
|
||||
@ -347,7 +343,6 @@ on this data set, we get:</p>
|
||||
<span class="co"># Table 5 - Acinetobacter spp.... OK.</span>
|
||||
<span class="co"># Warning: in `mdro()`: NA introduced for isolates where the available percentage of</span>
|
||||
<span class="co"># antimicrobial classes was below 50% (set with `pct_required_classes`)</span></code></pre></div>
|
||||
<<<<<<< HEAD
|
||||
<p>Only results with ‘R’ are considered as resistance. Use
|
||||
<code>combine_SI = FALSE</code> to also consider ‘I’ as resistance.</p>
|
||||
<p>Determining multidrug-resistant organisms (MDRO), according to:
|
||||
@ -357,10 +352,6 @@ standard definitions for acquired resistance. Author(s): Magiorakos AP,
|
||||
Srinivasan A, Carey RB, …, Vatopoulos A, Weber JT, Monnet DL Source:
|
||||
Clinical Microbiology and Infection 18:3, 2012; doi:
|
||||
10.1111/j.1469-0691.2011.03570.x</p>
|
||||
=======
|
||||
<p>Only results with ‘R’ are considered as resistance. Use <code>combine_SI = FALSE</code> to also consider ‘I’ as resistance.</p>
|
||||
<p>Determining multidrug-resistant organisms (MDRO), according to: Guideline: Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Author(s): Magiorakos AP, Srinivasan A, Carey RB, …, Vatopoulos A, Weber JT, Monnet DL Source: Clinical Microbiology and Infection 18:3, 2012; doi: 10.1111/j.1469-0691.2011.03570.x</p>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
<p>(16 isolates had no test results)</p>
|
||||
<p><strong>Frequency table</strong></p>
|
||||
<p>Class: factor > ordered (numeric)<br>
|
||||
@ -431,38 +422,21 @@ names or codes, this would have worked exactly the same way:</p>
|
||||
<div class="sourceCode" id="cb8"><pre class="downlit sourceCode r">
|
||||
<code class="sourceCode R"><span class="fu"><a href="https://rdrr.io/r/utils/head.html" class="external-link">head</a></span><span class="op">(</span><span class="va">my_TB_data</span><span class="op">)</span>
|
||||
<span class="co"># rifampicin isoniazid gatifloxacin ethambutol pyrazinamide moxifloxacin</span>
|
||||
<<<<<<< HEAD
|
||||
<span class="co"># 1 R S S I S I</span>
|
||||
<span class="co"># 2 R S S S R I</span>
|
||||
<span class="co"># 3 S S I I S S</span>
|
||||
<span class="co"># 4 I I S S S S</span>
|
||||
<span class="co"># 5 I R R I R R</span>
|
||||
<span class="co"># 6 I R S I S S</span>
|
||||
<span class="co"># 1 I S I I S S</span>
|
||||
<span class="co"># 2 R S I S R R</span>
|
||||
<span class="co"># 3 I R I S R S</span>
|
||||
<span class="co"># 4 I I I R S R</span>
|
||||
<span class="co"># 5 R S I R S I</span>
|
||||
<span class="co"># 6 S S I S R R</span>
|
||||
<span class="co"># kanamycin</span>
|
||||
<span class="co"># 1 I</span>
|
||||
<span class="co"># 2 R</span>
|
||||
<span class="co"># 3 R</span>
|
||||
<span class="co"># 1 R</span>
|
||||
<span class="co"># 2 I</span>
|
||||
<span class="co"># 3 S</span>
|
||||
<span class="co"># 4 S</span>
|
||||
<span class="co"># 5 I</span>
|
||||
<span class="co"># 6 I</span></code></pre></div>
|
||||
<span class="co"># 5 S</span>
|
||||
<span class="co"># 6 R</span></code></pre></div>
|
||||
<p>We can now add the interpretation of MDR-TB to our data set. You can
|
||||
use:</p>
|
||||
=======
|
||||
<span class="co"># 1 I R I R I I</span>
|
||||
<span class="co"># 2 I R I I I I</span>
|
||||
<span class="co"># 3 S I I R S S</span>
|
||||
<span class="co"># 4 R I R I R I</span>
|
||||
<span class="co"># 5 S I S S R S</span>
|
||||
<span class="co"># 6 S S I I I S</span>
|
||||
<span class="co"># kanamycin</span>
|
||||
<span class="co"># 1 I</span>
|
||||
<span class="co"># 2 R</span>
|
||||
<span class="co"># 3 I</span>
|
||||
<span class="co"># 4 I</span>
|
||||
<span class="co"># 5 R</span>
|
||||
<span class="co"># 6 R</span></code></pre></div>
|
||||
<p>We can now add the interpretation of MDR-TB to our data set. You can use:</p>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
<div class="sourceCode" id="cb9"><pre class="downlit sourceCode r">
|
||||
<code class="sourceCode R"><span class="fu"><a href="../reference/mdro.html">mdro</a></span><span class="op">(</span><span class="va">my_TB_data</span>, guideline <span class="op">=</span> <span class="st">"TB"</span><span class="op">)</span></code></pre></div>
|
||||
<p>or its shortcut <code><a href="../reference/mdro.html">mdr_tb()</a></code>:</p>
|
||||
@ -488,12 +462,8 @@ use:</p>
|
||||
<p><strong>Frequency table</strong></p>
|
||||
<p>Class: factor > ordered (numeric)<br>
|
||||
Length: 5,000<br>
|
||||
<<<<<<< HEAD
|
||||
Levels: 5: Negative < Mono-resistant < Poly-resistant <
|
||||
Multi-drug-resistant <…<br>
|
||||
=======
|
||||
Levels: 5: Negative < Mono-resistant < Poly-resistant < Multi-drug-resistant <…<br>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
Available: 5,000 (100%, NA: 0 = 0%)<br>
|
||||
Unique: 5</p>
|
||||
<table style="width:100%;" class="table">
|
||||
@ -517,73 +487,40 @@ Unique: 5</p>
|
||||
<tr class="odd">
|
||||
<td align="left">1</td>
|
||||
<td align="left">Mono-resistant</td>
|
||||
<<<<<<< HEAD
|
||||
<td align="right">3175</td>
|
||||
<td align="right">63.50%</td>
|
||||
<td align="right">3175</td>
|
||||
<td align="right">63.50%</td>
|
||||
=======
|
||||
<td align="right">3243</td>
|
||||
<td align="right">64.86%</td>
|
||||
<td align="right">3243</td>
|
||||
<td align="right">64.86%</td>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
<td align="right">3261</td>
|
||||
<td align="right">65.22%</td>
|
||||
<td align="right">3261</td>
|
||||
<td align="right">65.22%</td>
|
||||
</tr>
|
||||
<tr class="even">
|
||||
<td align="left">2</td>
|
||||
<td align="left">Negative</td>
|
||||
<<<<<<< HEAD
|
||||
<td align="right">1057</td>
|
||||
<td align="right">21.14%</td>
|
||||
<td align="right">4232</td>
|
||||
<td align="right">84.64%</td>
|
||||
=======
|
||||
<td align="right">969</td>
|
||||
<td align="right">19.38%</td>
|
||||
<td align="right">4212</td>
|
||||
<td align="right">84.24%</td>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
<td align="right">987</td>
|
||||
<td align="right">19.74%</td>
|
||||
<td align="right">4248</td>
|
||||
<td align="right">84.96%</td>
|
||||
</tr>
|
||||
<tr class="odd">
|
||||
<td align="left">3</td>
|
||||
<td align="left">Multi-drug-resistant</td>
|
||||
<<<<<<< HEAD
|
||||
<td align="right">431</td>
|
||||
<td align="right">8.62%</td>
|
||||
<td align="right">4663</td>
|
||||
<td align="right">93.26%</td>
|
||||
=======
|
||||
<td align="right">425</td>
|
||||
<td align="right">8.50%</td>
|
||||
<td align="right">4637</td>
|
||||
<td align="right">92.74%</td>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
<td align="right">437</td>
|
||||
<td align="right">8.74%</td>
|
||||
<td align="right">4685</td>
|
||||
<td align="right">93.70%</td>
|
||||
</tr>
|
||||
<tr class="even">
|
||||
<td align="left">4</td>
|
||||
<td align="left">Poly-resistant</td>
|
||||
<<<<<<< HEAD
|
||||
<td align="right">236</td>
|
||||
<td align="right">4.72%</td>
|
||||
<td align="right">4899</td>
|
||||
<td align="right">97.98%</td>
|
||||
=======
|
||||
<td align="right">263</td>
|
||||
<td align="right">5.26%</td>
|
||||
<td align="right">4900</td>
|
||||
<td align="right">98.00%</td>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
<td align="right">218</td>
|
||||
<td align="right">4.36%</td>
|
||||
<td align="right">4903</td>
|
||||
<td align="right">98.06%</td>
|
||||
</tr>
|
||||
<tr class="odd">
|
||||
<td align="left">5</td>
|
||||
<td align="left">Extensively drug-resistant</td>
|
||||
<<<<<<< HEAD
|
||||
<td align="right">101</td>
|
||||
<td align="right">2.02%</td>
|
||||
=======
|
||||
<td align="right">100</td>
|
||||
<td align="right">2.00%</td>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
<td align="right">97</td>
|
||||
<td align="right">1.94%</td>
|
||||
<td align="right">5000</td>
|
||||
<td align="right">100.00%</td>
|
||||
</tr>
|
||||
@ -608,12 +545,8 @@ Erwin E. A. Hassing.</p>
|
||||
|
||||
<div class="pkgdown">
|
||||
<p></p>
|
||||
<<<<<<< HEAD
|
||||
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a>
|
||||
2.0.2.</p>
|
||||
=======
|
||||
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.0.2.</p>
|
||||
>>>>>>> 8c9feea087f568fd4abbdb325140d1d628e6856f
|
||||
</div>
|
||||
|
||||
</footer>
|
||||
|
Reference in New Issue
Block a user